Golimumab Clinical Trials (2026): 102 Studies for Rheumatoid Arthritis & Colitis, Ulcerative
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
102 Golimumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 39 indications (including Rheumatoid Arthritis & Colitis, Ulcerative) and 35,502 total planned enrollment. 31 Phase 3 Golimumab trials and 17 Phase 2, 22 Phase 4 are listed. 7 Golimumab clinical trials are actively recruiting at 16 U.S. sites across 11 states. Most recent activity: NCT04725422 (Aug 2050).
Where to Participate: All Golimumab Trial Sites in the U.S. (16 sites across 11 states)
Every actively recruiting Golimumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Family Arthritis Center | Loxahatchee Groves33470 | NCT05669833 | Map |
| FL | Healing Rheumatology | Plant City33563 | NCT05669833 | Map |
| FL | Southwest Florida Rheumatology | Riverview33569 | NCT05669833 | Map |
| GA | Parris and Associates | Lilburn30047 | NCT05669833 | Map |
| MA | University of Massachusetts Chan Medical School | Worcester01655 | NCT05669833 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT03414502 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05669833 | Map |
| NY | New York University | New York10016 | NCT05669833 | Map |
| OH | Cincy Arthritis | Blue Ash45242 | NCT05669833 | Map |
| OH | Southern Ohio Rheumatology | Wheelersburg45694 | NCT05669833 | Map |
| PA | Hospital at the University of Pennsylvania | Philadelphia19104 | NCT05669833 | Map |
| TN | Cumberland Rheumatology | Crossville38555 | NCT05669833 | Map |
| TX | Heritage Rheumatology and Arthritis Care | Colleyville76034 | NCT05669833 | Map |
| TX | Texas Arthritis Center | El Paso79902 | NCT05669833 | Map |
| UT | University of Utah | Salt Lake City84132 | NCT05669833 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT04725422 | Map |
Golimumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | no longer available | Total |
|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||||||
| P1 | 5 | 5 | |||||||
| P1/P2 | 1 | 1 | |||||||
| P2 | 1 | 3 | 8 | 2 | 2 | 1 | 17 | ||
| P2/P3 | 1 | 1 | 2 | ||||||
| P3 | 2 | 1 | 23 | 4 | 1 | 31 | |||
| P4 | 1 | 14 | 2 | 5 | 22 | ||||
| N/A | 1 | 11 | 4 | 1 | 5 | 1 | 23 |
Recruiting Golimumab clinical trials (7)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04725422 | CHOIRCHronic Nonbacterial Osteomyelitis International Registry | — | Chronic Nonbacterial Osteomyelitis | 2,000 | Aug 2018 |
| NCT03414502 | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response | P3 | Rheumatoid Arthritis | 400 | Dec 2007 |
| NCT07258108 | Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors | P2 | Breast Cancer | 35 | Nov 2025 |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | Rheumatic Disease | 80 | Sep 2025 |
| NCT07495644 | Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt | — | Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) | 95 | Mar 2026 |
| NCT05669833 | EVOLUTIONGuselkumab vs Golimumab in PsA TNF Inadequate Responder Patients | P3 | Psoriatic Arthritis | 63 | Jul 2023 |
| NCT05313620 | Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events | P4 | Ulcerative Colitis | 30 | Apr 2022 |
Golimumab clinical trials by indication
Rheumatoid Arthritis (16)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03414502 | — | P3 | recruiting | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response |
| NCT05842213 | ALVOFLEX | P3 | completed | Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX |
| NCT03100253 | RAFTING | P4 | terminated | Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation |
| NCT01602302 | RA-BioStop | P4 | terminated | Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis |
| NCT02414984 | Go-Compl-Ar | N/A | terminated | Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab |
| NCT02390700 | GO-IV | N/A | terminated | Observational Study of Golimumab Intravenous Infusion |
| NCT01295151 | SWITCH | P4 | completed | SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. |
| NCT01081717 | — | N/A | completed | Golimumab Safety and Surveillance Program Using the Ingenix NHI Database |
| + 8 more, see All trials below. | ||||
Colitis, Ulcerative (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05242484 | DUET-UC | P2 | active not recruiting | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| NCT03596645 | PURSUIT 2 | P3 | active not recruiting | A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis |
| NCT01900574 | — | P1 | completed | A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis |
| NCT03662542 | VEGA | P2 | completed | A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| NCT03669029 | — | P4 | unknown | Optimization of Golimumab Treatment in Ulcerative Colitis |
| NCT02318667 | EVOLUTION | P4 | completed | Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). |
| NCT02412085 | UC-GOL | P4 | unknown | Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission |
| NCT01988961 | — | P2 | completed | A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| + 4 more, see All trials below. | ||||
Ulcerative Colitis (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05313620 | — | P4 | recruiting | Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events |
| NCT04156984 | — | P4 | completed | Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis |
| NCT05530122 | biological | N/A | completed | Prognosis in UC After First Biological |
| NCT03182166 | GOLILOR | P2 | completed | Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization |
| NCT05405465 | — | N/A | completed | Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland |
| NCT03018925 | GOLI2015 | N/A | completed | Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis |
| NCT03124121 | GO-LEVEL | P4 | completed | Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels |
| NCT03394586 | — | N/A | unknown | Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab |
| + 3 more, see All trials below. | ||||
Psoriatic Arthritis (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05669833 | EVOLUTION | P3 | recruiting | Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients |
| NCT04610476 | — | P3 | unknown | Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis |
| NCT04108468 | GOLMePsA | P3 | completed | GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA |
| NCT03955861 | — | N/A | completed | Ultrasound Enthesitis Response in Psoriatic Arthritis |
| NCT01871649 | — | P3 | completed | Initial Treatment With Golimumab in Early PsA |
| NCT02841176 | Go-Thermal | N/A | terminated | Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis |
| NCT02065713 | GO-DACT | P3 | completed | Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients |
Arthritis, Rheumatoid (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03729349 | GO FAR | N/A | completed | Golimumab for Adherence in Rheumatoid Arthritis |
| NCT04188249 | — | N/A | unknown | Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis |
| NCT02728934 | AWARE | N/A | completed | Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis |
| NCT01962974 | REGAIN | P3 | terminated | A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) |
| NCT00973479 | — | P3 | completed | An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy |
| NCT00299546 | CNTO 148 | P3 | completed | A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s) |
| NCT00975130 | GO-MORE | P3 | completed | Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) |
Ankylosing Spondylitis (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05164198 | RECAST | P4 | unknown | REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) |
| NCT03557853 | GO-COX | N/A | completed | Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab |
| NCT02758782 | CONSUL | P4 | completed | NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis |
| NCT02186873 | — | P3 | completed | A Study of Golimumab in Participants With Active Ankylosing Spondylitis |
| NCT01668004 | GO-EASY | P4 | completed | The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) |
| NCT01248793 | — | P3 | completed | Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis |
Arthritis, Psoriatic (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05071664 | AFFINITY | P2 | completed | A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis |
| NCT02181673 | — | P3 | completed | A Study of Golimumab in Participants With Active Psoriatic Arthritis |
| NCT00265096 | GO-REVEAL | P3 | completed | A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis |
Diabetes Mellitus, Type 1 (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04729296 | — | P2 | withdrawn | Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D |
| NCT02846545 | T1GER | P2 | completed | A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes |
| NCT03945903 | — | N/A | no longer available | Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults |
Spondylitis, Ankylosing (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03733925 | — | P4 | completed | A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis |
| NCT01453725 | GO-AHEAD | P3 | completed | Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) |
| NCT00265083 | — | P3 | completed | A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis |
Axial Spondyloarthritis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03270501 | GO-GUT | P3 | completed | Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation |
| NCT02437162 | — | P3 | terminated | A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis |
| NCT02438787 | — | P3 | terminated | A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis |
Major Depressive Disorder (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04156425 | — | N/A | unknown | The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression |
| NCT04531423 | — | N/A | unknown | PKC as Serum Biomarkers for Depression |
Spondyloarthritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03253796 | GO-BACK | P4 | completed | Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038) |
| NCT01610947 | SPACING | N/A | completed | Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity |
Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07495644 | — | N/A | not yet recruiting | Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt |
Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07258108 | — | P2 | recruiting | Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors |
Rheumatic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07138898 | — | P2 | not yet recruiting | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
Metastatic Castration-Resistant Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05960578 | — | P2 | active not recruiting | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study |
Crohn's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05242471 | DUET-CD | P2 | active not recruiting | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease |
Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04115423 | — | N/A | unknown | A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab |
Behcet Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04218565 | — | P2 | terminated | Golimumab for the Treatment of Refractory Behcet's Uveitis |
Inflammatory Bowel Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03885713 | BioIBD | P4 | completed | Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease |
Type 1 Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03632759 | — | Early P1 | completed | Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D |
Chronic Nonbacterial Osteomyelitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04725422 | CHOIR | N/A | recruiting | CHronic Nonbacterial Osteomyelitis International Registry |
Pre-Symptomatic Type 1 Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03298542 | — | P1 | completed | A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes |
ULCERATIVE COLITIS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02425865 | In-TARGET | P4 | completed | Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET |
RheumatoId Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03016260 | RABIOPRED | N/A | terminated | RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis |
Colitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02687724 | GOAL-ARC | P4 | unknown | Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis |
Inflammatory Bowel Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03043677 | — | N/A | completed | Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells |
Arthritis, Juvenile (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02277444 | GO-VIVA | P3 | completed | A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy |
Hepatosplenic T-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01804166 | HSTCL | P4 | completed | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) |
Spondyloarthropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01718951 | — | P4 | completed | Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial |
Autoimmune Inner Ear Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01526174 | AIED | P1/P2 | terminated | Intratympanic Injection for Autoimmune Inner Ear Disease |
Peripheral Spondylarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01426815 | CRESPA | P3 | completed | Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria |
Juvenile Idiopathic Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01230827 | JIA | P3 | terminated | A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01258777 | — | P1 | completed | A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects |
Healthy Adult Chinese Males (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01288157 | — | P1 | completed | A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects |
JIA Associated Uveitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04200833 | — | N/A | completed | Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab |
Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01004432 | ENBREL | P3 | completed | Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) |
Sarcoidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00955279 | SC | P2 | completed | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis |
Asthma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00675649 | — | P2 | withdrawn | A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma |
Golimumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| BioIBD | NCT03885713 | P4 | completed | Inflammatory Bowel Diseases | 180 | PMID 26353983 |
| RECAST | NCT05164198 | P4 | unknown | Ankylosing Spondylitis | 448 | — |
| In-TARGET | NCT02425865 | P4 | completed | ULCERATIVE COLITIS | 202 | — |
| RAFTING | NCT03100253 | P4 | terminated | Rheumatoid Arthritis | 208 | — |
| GO-BACK | NCT03253796 | P4 | completed | Spondyloarthritis | 323 | PMID 36919768 |
| CONSUL | NCT02758782 | P4 | completed | Ankylosing Spondylitis | 156 | PMID 28601821 |
| RA-BioStop | NCT01602302 | P4 | terminated | Rheumatoid Arthritis | 40 | — |
| GOAL-ARC | NCT02687724 | P4 | unknown | Colitis | 136 | — |
| HSTCL | NCT01804166 | P4 | completed | Hepatosplenic T-Cell Lymphoma | 1 | — |
| GO-LEVEL | NCT03124121 | P4 | completed | Ulcerative Colitis | 112 | PMID 32506695 |
| EVOLUTION | NCT02318667 | P4 | completed | Colitis, Ulcerative | 38 | PMID 31516554 |
| UC-GOL | NCT02412085 | P4 | unknown | Colitis, Ulcerative | 100 | — |
| GO-COLITIS | NCT02092285 | P4 | completed | Ulcerative Colitis | 205 | PMID 30002864 |
| PIMS | NCT02186886 | P4 | unknown | Ulcerative Colitis | 50 | — |
| SWITCH | NCT01295151 | P4 | completed | Rheumatoid Arthritis | 122 | PMID 32859608 |
| SMART | NCT02155335 | P4 | completed | Ulcerative Colitis | 100 | PMID 29920582 |
| GO-EASY | NCT01668004 | P4 | completed | Ankylosing Spondylitis | 101 | PMID 30385705 |
| PURSUIT 2 | NCT03596645 | P3 | active not recruiting | Colitis, Ulcerative | 84 | PMID 41503939 |
| EVOLUTION | NCT05669833 | P3 | recruiting | Psoriatic Arthritis | 63 | PMID 40102973 |
| GO-VIVA | NCT02277444 | P3 | completed | Arthritis, Juvenile | 130 | PMID 33493312 |
| ALVOFLEX | NCT05842213 | P3 | completed | Rheumatoid Arthritis | 502 | PMID 41182658 |
| GO-GUT | NCT03270501 | P3 | completed | Axial Spondyloarthritis | 64 | PMID 23139267 |
| GOLMePsA | NCT04108468 | P3 | completed | Psoriatic Arthritis | 84 | — |
| CRESPA | NCT01426815 | P3 | completed | Peripheral Spondylarthritis | 60 | PMID 36200875 |
| GO-DACT | NCT02065713 | P3 | completed | Psoriatic Arthritis | 44 | PMID 32193187 |
| CNTO 148 | NCT00488631 | P3 | completed | Colitis, Ulcerative | 1,228 | PMID 37691729 |
| GO-AHEAD | NCT01453725 | P3 | completed | Spondylitis, Ankylosing | 198 | PMID 26139307 |
| REGAIN | NCT01962974 | P3 | terminated | Arthritis, Rheumatoid | 7 | — |
| JIA | NCT01230827 | P3 | terminated | Juvenile Idiopathic Arthritis | 173 | PMID 28507219 |
| ENBREL | NCT01004432 | P3 | completed | Arthritis | 433 | PMID 28035867 |
| CNTO 148 | NCT00299546 | P3 | completed | Arthritis, Rheumatoid | 461 | PMID 27889300 |
| GO-FORWARD | NCT00264550 | P3 | completed | Rheumatoid Arthritis | 444 | PMID 21083889 |
| GO-MORE | NCT00975130 | P3 | completed | Arthritis, Rheumatoid | 3,366 | PMID 23740226 |
| GO-REVEAL | NCT00265096 | P3 | completed | Arthritis, Psoriatic | 407 | PMID 27803138 |
| DUET-CD | NCT05242471 | P2 | active not recruiting | Crohn's Disease | 703 | — |
| DUET-UC | NCT05242484 | P2 | active not recruiting | Colitis, Ulcerative | 577 | — |
| AFFINITY | NCT05071664 | P2 | completed | Arthritis, Psoriatic | 91 | — |
| GOLILOR | NCT03182166 | P2 | completed | Ulcerative Colitis | 51 | — |
| VEGA | NCT03662542 | P2 | completed | Colitis, Ulcerative | 214 | PMID 38488354 |
| T1GER | NCT02846545 | P2 | completed | Diabetes Mellitus, Type 1 | 84 | PMID 33207093 |
| SC | NCT00955279 | P2 | completed | Sarcoidosis | 173 | PMID 25594886 |
| REGN88 | NCT01217814 | P2 | terminated | Rheumatoid Arthritis | 16 | — |
Terminated and withdrawn Golimumab trials (16)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04729296withdrawnAnti-TNFα to Delay or Prevent Progression to Stage 3 T1D
- NCT04218565terminatedGolimumab for the Treatment of Refractory Behcet's Uveitis
- NCT03100253terminatedRheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
- NCT01602302terminatedUltrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis
- NCT03016260terminatedRABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis
- NCT02841176terminatedThermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis
- NCT02437162terminatedA Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
- NCT02438787terminatedA Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
- NCT02414984terminatedRegistry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab
- NCT02390700terminatedObservational Study of Golimumab Intravenous Infusion
- NCT01962974terminatedA Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
- NCT01230827terminatedA Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
- NCT01526174terminatedIntratympanic Injection for Autoimmune Inner Ear Disease
- NCT01217814terminatedEffect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
- NCT00488774terminatedAn Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
- NCT00675649withdrawnA Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma
All Golimumab trials (102)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04725422 | CHOIR | CHronic Nonbacterial Osteomyelitis International Registry | — | recruiting | 2,000 | Seattle Children's Hospital | Aug 2018 |
| NCT05242471 | DUET-CD | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | P2 | active not recruiting | 703 | Janssen Research & Development, LLC | Jul 2022 |
| NCT03414502 | Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response | P3 | recruiting | 400 | University of Nebraska | Dec 2007 | |
| NCT05242484 | DUET-UC | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | P2 | active not recruiting | 577 | Janssen Research & Development, LLC | Sep 2022 |
| NCT07258108 | Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors | P2 | recruiting | 35 | Sun Yat-sen University | Nov 2025 | |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | not yet recruiting | 80 | NYU Langone Health | Sep 2025 | |
| NCT04729296 | Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D | P2 | withdrawn | 0 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Jul 2021 | |
| NCT07495644 | Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt | — | not yet recruiting | 95 | Assiut University | Mar 2026 | |
| NCT05960578 | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | P2 | active not recruiting | 8 | University of Washington | May 2024 | |
| NCT03596645 | PURSUIT 2 | A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | P3 | active not recruiting | 84 | Janssen Research & Development, LLC | Oct 2018 |
| NCT05669833 | EVOLUTION | Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients | P3 | recruiting | 63 | University of Pennsylvania | Jul 2023 |
| NCT05313620 | Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events | P4 | recruiting | 30 | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Apr 2022 | |
| NCT04610476 | Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis | P3 | unknown | 270 | University of Erlangen-Nürnberg Medical School | Oct 2020 | |
| NCT04156425 | The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression | N/A | unknown | 180 | Shanghai Mental Health Center | Jul 2020 | |
| NCT03885713 | BioIBD | Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease | P4 | completed | 180 | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Sep 2019 |
| NCT05164198 | RECAST | REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) | P4 | unknown | 448 | Hanyang University Seoul Hospital | Jan 2022 |
| NCT02277444 | GO-VIVA | A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy | P3 | completed | 130 | Janssen Research & Development, LLC | Dec 2014 |
| NCT05842213 | ALVOFLEX | Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX | P3 | completed | 502 | Alvotech Swiss AG | Mar 2023 |
| NCT05071664 | AFFINITY | A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis | P2 | completed | 91 | Janssen Research & Development, LLC | Oct 2021 |
| NCT04156984 | Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis | P4 | completed | 27 | David Drobne | Apr 2021 | |
| NCT03270501 | GO-GUT | Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation | P3 | completed | 64 | University Ghent | Nov 2017 |
| NCT04108468 | GOLMePsA | GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA | P3 | completed | 84 | The Leeds Teaching Hospitals NHS Trust | Oct 2015 |
| NCT03729349 | GO FAR | Golimumab for Adherence in Rheumatoid Arthritis | — | completed | 222 | Janssen Inc. | Jan 2019 |
| NCT02425865 | In-TARGET | Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET | P4 | completed | 202 | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Dec 2016 |
| NCT04218565 | Golimumab for the Treatment of Refractory Behcet's Uveitis | P2 | terminated | 1 | Wenjie Zheng | Feb 2020 | |
| NCT04531423 | PKC as Serum Biomarkers for Depression | N/A | unknown | 100 | Shanghai Mental Health Center | Oct 2020 | |
| NCT01900574 | A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis | P1 | completed | 35 | Janssen Research & Development, LLC | Aug 2013 | |
| NCT05530122 | biological | Prognosis in UC After First Biological | — | completed | 192 | Tampere University Hospital | Jan 2009 |
| NCT03100253 | RAFTING | Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation | P4 | terminated | 208 | Mario Negri Institute for Pharmacological Research | Mar 2018 |
| NCT03182166 | GOLILOR | Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization | P2 | completed | 51 | Centre Hospitalier Universitaire de Saint Etienne | Nov 2017 |
| NCT03733925 | A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis | P4 | completed | 100 | Johnson & Johnson Private Limited | Jan 2019 | |
| NCT03662542 | VEGA | A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | P2 | completed | 214 | Janssen Research & Development, LLC | Nov 2018 |
| NCT03632759 | Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D | Early P1 | completed | 16 | Carla Greenbaum, MD | Aug 2018 | |
| NCT04115423 | A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab | — | unknown | 9,508 | Sungkyunkwan University | Apr 2020 | |
| NCT04200833 | Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab | — | completed | 10 | Medical University of Graz | Mar 2010 | |
| NCT03955861 | Ultrasound Enthesitis Response in Psoriatic Arthritis | — | completed | 80 | Belfast Health and Social Care Trust | Feb 2019 | |
| NCT03557853 | GO-COX | Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab | — | completed | 39 | MSD Pharmaceuticals LLC | Jun 2016 |
| NCT05405465 | Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland | — | completed | 103 | University of Zurich | Jan 2018 | |
| NCT03298542 | A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes | P1 | completed | 8 | Janssen Research & Development, LLC | Oct 2017 | |
| NCT03253796 | GO-BACK | Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038) | P4 | completed | 323 | Merck Sharp & Dohme LLC | Nov 2017 |
| NCT04188249 | Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis | — | unknown | 200 | Peking Union Medical College Hospital | Jul 2019 | |
| NCT02758782 | CONSUL | NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis | P4 | completed | 156 | Charite University, Berlin, Germany | Sep 2016 |
| NCT02846545 | T1GER | A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes | P2 | completed | 84 | Janssen Research & Development, LLC | Aug 2016 |
| NCT01602302 | RA-BioStop | Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis | P4 | terminated | 40 | Medical University of Graz | Jun 2012 |
| NCT03018925 | GOLI2015 | Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis | — | completed | 15 | Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta | Oct 2016 |
| NCT02687724 | GOAL-ARC | Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis | P4 | unknown | 136 | University College Dublin | Jun 2016 |
| NCT01804166 | HSTCL | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | P4 | completed | 1 | Janssen Scientific Affairs, LLC | Mar 2013 |
| NCT02728934 | AWARE | Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis | — | completed | 1,279 | Janssen Scientific Affairs, LLC | Feb 2016 |
| NCT03669029 | Optimization of Golimumab Treatment in Ulcerative Colitis | P4 | unknown | 50 | Hospital de Manises | Oct 2018 | |
| NCT03016260 | RABIOPRED | RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis | — | terminated | 250 | TcLand Expression S.A. | Dec 2016 |
| NCT03124121 | GO-LEVEL | Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels | P4 | completed | 112 | Guy's and St Thomas' NHS Foundation Trust | Sep 2017 |
| NCT03945903 | Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults | — | no longer available | 0 | Janssen Research & Development, LLC | — | |
| NCT01426815 | CRESPA | Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria | P3 | completed | 60 | University Hospital, Ghent | Mar 2012 |
| NCT03394586 | Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab | — | unknown | 100 | University of Zurich | Jan 2018 | |
| NCT01871649 | Initial Treatment With Golimumab in Early PsA | P3 | completed | 51 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Aug 2013 | |
| NCT01610947 | SPACING | Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity | N/A | completed | 398 | University Hospital, Montpellier | May 2012 |
| NCT03043677 | Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells | — | completed | 45 | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Apr 2016 | |
| NCT02841176 | Go-Thermal | Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis | N/A | terminated | 4 | Imperial College Healthcare NHS Trust | Jul 2016 |
| NCT02437162 | A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis | P3 | terminated | 347 | Janssen Research & Development, LLC | Sep 2015 | |
| NCT02318667 | EVOLUTION | Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). | P4 | completed | 38 | Merck Sharp & Dohme LLC | Feb 2015 |
| NCT02438787 | A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis | P3 | terminated | 315 | Janssen Research & Development, LLC | Jul 2015 | |
| NCT02065713 | GO-DACT | Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients | P3 | completed | 44 | Instituto de Medicina Molecular João Lobo Antunes | Aug 2014 |
| NCT02181673 | A Study of Golimumab in Participants With Active Psoriatic Arthritis | P3 | completed | 480 | Janssen Research & Development, LLC | Sep 2014 | |
| NCT02412085 | UC-GOL | Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission | P4 | unknown | 100 | Istituto Clinico Humanitas | Mar 2015 |
| NCT02414984 | Go-Compl-Ar | Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab | — | terminated | 37 | Janssen-Cilag, S.A. | Mar 2015 |
| NCT02390700 | GO-IV | Observational Study of Golimumab Intravenous Infusion | — | terminated | 78 | Janssen Inc. | Feb 2015 |
| NCT02186873 | A Study of Golimumab in Participants With Active Ankylosing Spondylitis | P3 | completed | 208 | Janssen Research & Development, LLC | Sep 2014 | |
| NCT02092285 | GO-COLITIS | Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) | P4 | completed | 205 | Merck Sharp & Dohme LLC | May 2014 |
| NCT01988961 | A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | P2 | completed | 103 | Janssen Research & Development, LLC | Dec 2013 | |
| NCT01863771 | A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis. | P3 | completed | 144 | Janssen Pharmaceutical K.K. | Mar 2013 | |
| NCT02186886 | PIMS | Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab | P4 | unknown | 50 | Kliniken im Naturpark Altmuehltal | Jun 2014 |
| NCT01295151 | SWITCH | SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | P4 | completed | 122 | Julia Brown | Aug 2011 |
| NCT02155335 | SMART | Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) | P4 | completed | 100 | Merck Sharp & Dohme LLC | Jul 2014 |
| NCT01081717 | Golimumab Safety and Surveillance Program Using the Ingenix NHI Database | — | completed | 1,064 | Janssen Biotech, Inc. | Apr 2009 | |
| NCT01668004 | GO-EASY | The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) | P4 | completed | 101 | Merck Sharp & Dohme LLC | Sep 2012 |
| NCT01715896 | A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis | P2 | completed | 215 | MedImmune LLC | Mar 2013 | |
| NCT00488631 | CNTO 148 | An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis | P3 | completed | 1,228 | Janssen Research & Development, LLC | Sep 2007 |
| NCT01453725 | GO-AHEAD | Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) | P3 | completed | 198 | Merck Sharp & Dohme LLC | Feb 2012 |
| NCT01962974 | REGAIN | A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) | P3 | terminated | 7 | Janssen Biotech, Inc. | Oct 2013 |
| NCT01718951 | Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial | P4 | completed | 30 | Tuen Mun Hospital | Aug 2012 | |
| NCT01230827 | JIA | A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) | P3 | terminated | 173 | Janssen Research & Development, LLC | Dec 2010 |
| NCT01526174 | AIED | Intratympanic Injection for Autoimmune Inner Ear Disease | P1/P2 | terminated | 16 | House Research Institute | Mar 2012 |
| NCT01004432 | ENBREL | Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) | P3 | completed | 433 | Janssen Biotech, Inc. | Dec 2009 |
| NCT00973479 | An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy | P3 | completed | 592 | Centocor, Inc. | Sep 2009 | |
| NCT00955279 | SC | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis | P2 | completed | 173 | Centocor, Inc. | Nov 2009 |
| NCT01248780 | Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy | P3 | completed | 264 | Centocor, Inc. | Sep 2010 | |
| NCT00264537 | A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive | P3 | completed | 637 | Centocor, Inc. | Dec 2005 | |
| NCT00299546 | CNTO 148 | A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s) | P3 | completed | 461 | Centocor, Inc. | Feb 2006 |
| NCT00264550 | GO-FORWARD | An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy | P3 | completed | 444 | Centocor, Inc. | Dec 2005 |
| NCT01248793 | Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis | P3 | completed | 213 | Centocor, Inc. | Oct 2010 | |
| NCT00975130 | GO-MORE | Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) | P3 | completed | 3,366 | Merck Sharp & Dohme LLC | Sep 2009 |
| NCT00265083 | A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis | P3 | completed | 356 | Centocor, Inc. | Dec 2005 | |
| NCT00265096 | GO-REVEAL | A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis | P3 | completed | 407 | Centocor, Inc. | Dec 2005 |
| NCT01217814 | REGN88 | Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers | P2 | terminated | 16 | Sanofi | Nov 2010 |
| NCT01258777 | A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects | P1 | completed | 49 | Centocor, Inc. | Oct 2010 | |
| NCT01288157 | A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects | P1 | completed | 24 | Centocor, Inc. | Sep 2010 | |
| NCT00487539 | CNTO 148 | An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis | P2/P3 | completed | 1,065 | Janssen Research & Development, LLC | Aug 2007 |
| NCT00361335 | A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy | P3 | completed | 643 | Centocor, Inc. | Sep 2006 | |
| NCT00488774 | An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis | P2/P3 | terminated | 291 | Janssen Research & Development, LLC | Aug 2007 | |
| NCT01362153 | PK | A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA) | P1 | completed | 49 | Centocor, Inc. | Dec 2007 |
| NCT00675649 | A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma | P2 | withdrawn | 0 | Centocor, Inc. | May 2008 | |
| NCT00207714 | An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis | P2 | completed | 172 | Centocor, Inc. | Nov 2003 |
Golimumab clinical trials: frequently asked questions
- How many Golimumab clinical trials are there?
- 102 Golimumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 63 are marked completed.
- Are Golimumab clinical trials recruiting in 2026?
- Yes — 5 Golimumab trials are actively recruiting in 2026, with 16 U.S. sites across 11 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Golimumab being studied for?
- Golimumab is being studied for Rheumatoid Arthritis, Colitis, Ulcerative, Ulcerative Colitis, Arthritis, Rheumatoid, Ankylosing Spondylitis and 47 more. The trials are grouped by indication on this page.
- What phase is Golimumab in?
- Golimumab clinical trials span 22 Phase 4, 31 Phase 3, 17 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Golimumab clinical trials?
- The lead sponsor across the most Golimumab trials is Janssen Research & Development, LLC, with 54 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Golimumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: